Overview

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Status:
Suspended

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

- An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation - The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation

Phase:

Phase 1

Details

Lead Sponsor:

Piramal Enterprises Limited

Collaborator:

Melanoma Research Foundation Breakthrough Consortium

Treatments:

Vemurafenib